Smolen et al61 found that only a fraction of gastric cancer cell lines appeared to be extraordinarily vulnerable to the selective MET inhibitor PHA‐665752, and these cells were found to have high‐level amplification of wild‐type MET. This evidence concerns the gene MET and gastric cancer.